

1 **A pharmacoepidemiological study of myocarditis and pericarditis following mRNA**

2 **COVID-19 vaccination in Europe**

3 Joana Tome, MPH¹, Logan T. Cowan, PhD¹, Isaac Chun-Hai Fung, PhD^{1*}

4 ¹ *Department of Biostatistics, Epidemiology, and Environmental Health Sciences, Jiann-Ping*

5 *Hsu College of Public Health, Georgia Southern University, Statesboro, Georgia, United States*

6
7 * Author to whom correspondence should be addressed. Isaac Chun-Hai Fung, PhD, Department

8 of Biostatistics, Epidemiology and Environmental Health Sciences, Jiann-Ping Hsu College of

9 Public Health, Georgia Southern University, PO Box 7989, Statesboro, GA 30460, USA. Tel: +1

10 912-478-5079, Fax: +1 912-478-0171, cfung@georgiasouthern.edu, *ORCID 0000-0001-5496-*

11 2529

12
13 Disclaimer: The views expressed in the submitted manuscript are ours and not an official

14 position of any institution or funder.

15 Source(s) of support: None

16 Word Count (excluding abstract, captions, references): 3,339

17 Number of tables: 4

25 **ABSTRACT**

26 **Purpose:** To assess myocarditis and pericarditis reporting rate as adverse drug reactions (ADRs)
27 for the messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccines
28 authorized in Europe.

29 **Methods:** Data on myocarditis and pericarditis related to mRNA COVID-19 vaccines (period:
30 January 1, 2021 - February 11, 2022) were collected from the EudraVigilance database and
31 combined with the European Centre for Disease Prevention and Control's (ECDC) vaccination
32 tracker database. The reporting rate was expressed as 1 million individual vaccinated-days with a
33 corresponding 95% confidence interval (CI), and an observed-to-expected (OE) analysis was
34 performed to check if there was an excess risk for myocarditis or pericarditis following mRNA
35 COVID-19 vaccination.

36 **Results:** The reporting rate of myocarditis per 1 million individual vaccinated-days in the study
37 period was 17.27 (95% CI, 16.34-18.26) for the CX-024414 vaccine and 8.44 (95% CI, 8.18-
38 8.70) for TOZINAMERAN vaccine. The reporting rate for pericarditis per 1 million individual
39 vaccinated-days in the study period was 9.76 (95% CI, 9.06-10.51) for the CX-024414 vaccine
40 and 5.79 (95% CI, 5.56-6.01) for TOZINAMERAN vaccine. The OE analysis showed that both
41 vaccines produced a myocarditis standardized morbidity ratio (SMR) greater than 1, with the
42 CX-024414 vaccine having a greater SMR than TOZINAMERAN. Regarding
43 TOZINAMERAN, SMR for pericarditis was greater than 1 when considering the lowest
44 background incidence, but smaller than 1 when considering the highest background incidence.

45 **Conclusions:** Our results suggest an excess risk of myocarditis following the first dose of
46 mRNA COVID-19 vaccine, but the relationship between pericarditis and mRNA COVID-19
47 vaccine remains unclear.

48 **KEYWORDS**

49 COVID-19; adverse drug reaction; myocarditis; pericarditis; COVID-19 mRNA vaccine.

50 **ABBREVIATIONS**

51 ADRs – adverse drug reactions

52 CI – confidence interval

53 COVID-19 – coronavirus disease 2019

54 ECDC – European Centre for Disease Prevention and Control

55 EEA – European Economic Area

56 EMA – European Medicines Agency

57 EU – European Union

58 mRNA – messenger ribonucleic acid

59 OE – observed-to-expected

60 OR – odds ratio

61 PRAC – Pharmacovigilance Risk Assessment Committee

62 RNA – ribonucleic acid

63 SARS-CoV-2 – severe acute respiratory syndrome coronavirus 2

64 SMR – standardized morbidity ratio

65

66

67

68

69

70

71 **INTRODUCTION**

72 Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the
73 heart's outer lining) following immunizations such as smallpox, influenza, hepatitis B, or other
74 vaccines have previously been reported as a rare side effect.¹⁻³ Depending on the source, the
75 incidence of myocarditis and pericarditis in the European Economic Area (EEA) has ranged
76 from 1 to 10 in 100,000 people per year.⁴ European Medicines Agency (EMA)'s safety
77 committee, the Pharmacovigilance Risk Assessment Committee (PRAC), started reviewing cases
78 of myocarditis and pericarditis following Pfizer-BioNTech (TOZINAMERAN) and Moderna
79 (CX-024414) COVID-19 vaccination since April 2021. Increased rates of cases of myocarditis
80 and pericarditis following mRNA COVID-19 vaccination were also noticed in the United States⁵
81 and Canada.⁶

82 TOZINAMERAN and CX-024414, the two mRNA vaccines being used in the European
83 Union (EU)/EEA, contain an mRNA molecule with instructions for producing the spike protein
84 from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that stimulates the body's
85 immune response.⁴ There are different biological mechanisms that can explain the possible
86 association between mRNA COVID-19 vaccination and the occurrence of myocarditis and
87 pericarditis. Based on preliminary evidence from adult trials with mRNA vaccinations, it is rare
88 but possible that antibody responses to mRNA vaccines can become very high, causing cardiac
89 inflammation.⁷ One other mechanism is the activation of anti-idiotypic cross-reactive antibody-
90 mediated cytokine expression in the myocardium, as well as abnormal apoptosis, which can
91 result in myocardial and pericardial inflammation.⁸ The mRNA vaccines may possibly trigger a
92 non-specific innate inflammatory response or a molecular mimicry mechanism between the viral

93 spike protein and an unknown cardiac protein.⁹ The last explanation is that vaccinations' potent
94 immunogenic RNA can have a bystander or adjuvant consequence on the heart.¹⁰

95 Although the occurrence of myocarditis and pericarditis following SARS-CoV-2
96 infection seems to be more frequent and serious,¹¹⁻¹³ assessing the risk of myocarditis and
97 pericarditis after COVID-19 mRNA immunization has its own importance.

98 Previous studies indicate that the incidence of myocarditis and pericarditis may increase
99 following COVID-19 mRNA immunization;¹⁴⁻¹⁸ therefore, it is critical to determine the
100 magnitude of the association between myocarditis or pericarditis occurrence and mRNA
101 COVID-19 vaccination in order to protect the most vulnerable population and to aid in the
102 differentiation of the COVID-19 vaccination's risks and benefits. Moreover, many clinical trials
103 were unable to identify rare adverse events of COVID-19 vaccines because they were
104 underpowered. Their detection is critical for risk-benefit analyses and informing post-vaccination
105 clinical practice. Therefore, detecting such adverse events through pharmacovigilance post-
106 authorization has become a global scientific priority.

107 To enhance risk communication that accompanies existing COVID-19 vaccination
108 campaigns, this study aims to quantify the elevated risk, if any, of myocarditis and pericarditis 28
109 days following Tozinameran and CX-024414 vaccination among Europeans using publicly
110 available data from the EU/EEA in an exploratory way. This study used an OE analysis, which is
111 a part of the quantitative pharmacovigilance toolkit for vaccines, to calculate the standardized
112 morbidity ratio (SMR).

113 **MATERIAL AND METHODS**

114 We hypothesize that myocarditis and pericarditis SMRs greater than 1 will result from
115 both the mRNA COVID-19 vaccines. A combination of two databases was used in this

116 pharmacoepidemiological study. The participants were European people from the EU/EEA
117 countries who were eligible for the mRNA COVID-19 vaccines that were available in Europe
118 during the 2021-2022 periods. All the variables included in this analysis are named/defined as
119 classified in their respective databases.

120 ECDC has a vaccination tracker database¹⁹ that gathers reports from the EU/EEA
121 countries. These countries submit data to the ECDC through The European Surveillance System
122 (TESSy) twice a week (Tuesdays and Fridays). The database contains aggregated data on the
123 number of vaccine doses distributed by manufacturers to the EU/EEA countries, the number of
124 first, second, additional, and unspecified doses administered to different age groups and in
125 specific target groups, such as healthcare workers and in residents in long-term care facilities.
126 The database includes data on the COVID-19 vaccination rollout, where each row contains the
127 corresponding data for a certain week and country. The database is publicly available and was
128 downloaded on February 16, 2022. From this database, we extracted the number of individuals
129 from the EU/EEA countries who received their first dose of CX-024414 and TOZINAMERAN
130 vaccines that also represents our exposure variable. Technically, being vaccinated with the first
131 dose of the CX-024414 or TOZINAMERAN vaccines (including a time window from the date
132 when the mRNA COVID-19 vaccines became eligible for vaccination in Europe till February 16,
133 2022) is considered as our exposure variable. In the analysis, it was used as the sum of the
134 individuals from the EU/EEA countries who received their first dose of CX-024414 and
135 TOZINAMERAN vaccines during the time window period, which also represents our study
136 population size.

137 EudraVigilance²⁰ is a public available pharmacovigilance database of suspected ADR
138 reports. Data was downloaded from EudraVigilance on February 16, 2022. The database

139 contains cardiac problems related to COVID-19 vaccination using mRNA vaccines (CX-024414
140 and TOZINAMERAN) reported from January 1, 2021, to February 11, 2022. Among all cardiac
141 problems, our outcomes of interest are myocarditis and pericarditis. The database contains the
142 EU local number (identification number), type of report, the date when the report was received,
143 the source of the report, age group, sex, the vaccine type, the adverse event, the duration,
144 outcome, and seriousness of the adverse event, the duration, dose, and the route of administration
145 of the vaccine, the type of concomitant, and the duration, dose, and the route of administration of
146 any concomitant received by the patient. In this analysis, we used the number of myocarditis and
147 pericarditis ADRs, the age group, sex, and the vaccine as the other needed variables. The ADR
148 outcomes were treated as the sum of the number of myocarditis or pericarditis reported in the
149 study period. Age group categories were classified as 5-11, 12-17, 18-64, 65-85 years old, more
150 than 85 years old, and not specified. Sex was classified as female, male, and not specified. The
151 vaccine variable was represented by the CX-024414 and TOZINAMERAN vaccines. No missing
152 data were observed from both the databases.

153 Myocarditis and pericarditis reporting rates during the study period (January 1, 2021, to
154 February 11, 2022) were estimated using the formulae: ²¹

155 -for myocarditis: $\frac{\text{the number of myocarditis ADRs reported in the study period}}{\text{the number of individuals who received their first dose of vaccine in the study period}}$

156 -for pericarditis: $\frac{\text{the number of pericarditis ADRs reported in the study period}}{\text{the number of individuals who received their first dose of vaccine in the study period}}$

157 The OE analysis was performed within 28 days post the first vaccine dose, considering
158 the estimated lowest and highest myocarditis and pericarditis background incidence rates
159 reported by the EMA.⁴ The background incidence rate represents the number of new cases
160 naturally occurring in the EEA, expressed as person-time, and was estimated for the EEA
161 population before it was exposed to any of the mRNA COVID-19 vaccines. The person-time at

162 risk was calculated as the number of first doses $\times (28/365.2425) \times (1/100,000)$.²¹ The OE ratio
163 was expressed as an SMR with a 95% CI.²¹ The analysis was performed using the ‘epiR’
164 package in R version 4.0.3 (R Core Team, R Foundation for Statistical Computing, Vienna,
165 Austria).

166 **Patient and public involvement**

167 Only publicly available data are used in this study. This study was determined by Georgia
168 Southern University’s Institution Review Board (IRB) (H20364) to be exempt from full review
169 under the G8 exemption category (Non-human subjects determination): This project does not
170 involve obtaining information about living individuals or does not have direct interaction or
171 intervention with individuals or their personal data so is not defined as human subjects research
172 under human subjects regulations. As well, no patient or public was involved in the study design
173 or the data collection, analysis, or interpretation procedures.

174 **RESULTS**

175 In the study period, there were 73,466,253 people in the EU who received the first dose
176 of the CX-024414 vaccine and 484,402,251 who received their first dose of the
177 TOZINAMERAN vaccine. In the same period, there were 9,078 and 38,297 individuals in
178 EU/EEA countries reported with adverse cardiac problems after the administration of the CX-
179 024414 vaccine and the TOZINAMERAN vaccine, respectively. Of these reports, there were
180 1,269 and 4,087 myocarditis events reported for CX-024414, and for TOZINAMERAN
181 respectively (**Table 1**), and 717 and 2,803 pericarditis events for CX-024414 and
182 TOZINAMERAN, respectively (**Table 2**). The reporting rate of myocarditis per 1 million
183 individual vaccinated-days in the study period was 17.27 (95% CI, 16.34-18.26) for the CX-
184 024414 vaccine and 8.44 (95% CI, 8.18-8.70) for TOZINAMERAN vaccine. The reporting rate

185 for pericarditis per 1 million individual vaccinated-days in the study period was 9.76 (95% CI,
 186 9.06-10.51) for the CX-024414 vaccine and 5.79 (95% CI, 5.56-6.01) for TOZINAMERAN
 187 vaccine.

188 **Table 1.** All myocarditis ADRs stratified by age group and sex.

| Vaccine name, <i>n</i> of total cardiac ADRs (Jan 1, 2021-Feb 11, 2022) | Patient Age Group | Patient Sex | | | Myocarditis ADRs n (%) |
|--|----------------------|----------------|----------------|-------------|------------------------------|
| | | Female | Male | NS | |
| Moderna (CX-024414) N=9,078 | 12-17 Years | 5 | 67 | 0 | 72 (5.67) |
| | 18-64 Years | 231 | 883 | 6 | 1,120 (88.26) |
| | 65-85 Years | 29 | 27 | 0 | 56 (4.41) |
| | More than 85 | 2 | 1 | 0 | 3 (0.24) |
| | Not Specified | 6 | 10 | 2 | 18 (1.42) |
| | Total (%) | 273 (21.51) | 988 (77.86) | 8 (0.63) | 1,269 (100) |
| Pfizer-BioNTech (TOZINAMERAN) N=38,297 | 5-11 Years | 3 | 4 | 0 | 7 (0.17) |
| | 12-17 Years | 65 | 492 | 5 | 562 (13.75) |
| | 18-64 Years | 897 | 2,187 | 22 | 3,106 (76.00) |
| | 65-85 Years | 122 | 122 | 2 | 246 (6.02) |
| | More than 85 | 11 | 12 | 0 | 23 (0.56) |

| Vaccine name, <i>n</i> of total cardiac ADRs (Jan 1, 2021-Feb 11, 2022) | Patient Age Group | Patient Sex | | | Myocarditis |
|--|----------------------|------------------|------------------|--------------|---------------|
| | | Female | Male | NS | ADRs n (%) |
| | Not Specified | 40 | 85 | 18 | 143 (3.50) |
| | Total (%) | 1,138 (27.84) | 2,902 (71.01) | 47 (1.15) | 4,087 (100) |

Abbreviations: ADRs, adverse drug reactions; n, number; NS, not specified.

189

190 **Table 2.** All pericarditis ADRs stratified by age group and sex.

| Vaccine name, <i>n</i> of total cardiac ADRs (Jan 1, 2021-Feb 11, 2022) | Patient Age Group | Patient Sex | | | Pericarditis |
|--|----------------------|-------------|------|----|---------------|
| | | Female | Male | NS | ADRs n (%) |
| Moderna (CX-024414) N=9,078 | 12-17 Years | 5 | 7 | 0 | 12 (1.67) |
| | 18-64 Years | 266 | 336 | 4 | 606 (84.52) |
| | 65-85 Years | 46 | 43 | 0 | 89 (12.41) |
| | More than 85 | 2 | 0 | 0 | 2 (0.28) |
| | Not Specified | 4 | 4 | 0 | 8 (1.12) |
| | Total (%) | 323 | 390 | 4 | 717 |

| Vaccine name, <i>n</i> of total cardiac ADRs (Jan 1, 2021-Feb 11, 2022) | Patient Age Group | Patient Sex | | | Pericarditis |
|--|----------------------|------------------|------------------|--------------|---------------|
| | | Female | Male | NS | ADRs |
| | | (45.05) | (54.39) | (0.56) | n (%) |
| Pfizer-BioNTech (TOZINAMERAN) N=38,297 | 12-17 Years | 49 | 89 | 0 | 138 (4.92) |
| | 18-64 Years | 1,157 | 1,068 | 10 | 2,235 (79.74) |
| | 65-85 Years | 160 | 184 | 0 | 344 (12.27) |
| | More than 85 | 15 | 25 | 0 | 40 (1.43) |
| | Not Specified | 24 | 20 | 2 | 46 (1.64) |
| | Total (%) | 1,405 (50.12) | 1,386 (49.45) | 12 (0.43) | 2,803 |

Abbreviations: ADRs, adverse drug reactions; n, number; NS, not specified.

191
192 **Tables 3 and 4** presented the OE analyses for both vaccines using two background
193 incidence rates, namely 1 and 10 per 100,000 persons per year, respectively. For myocarditis, the
194 results showed an SMR >1 for both vaccines, with the CX-024414 vaccine having a greater
195 SMR than that of TOZINAMERAN. For pericarditis, both vaccines had an SMR >1 when
196 considering the lowest background incidence; however, when the highest background incidence
197 was considered, the SMR for TOZINAMERAN was <1 while that for CX-024414 was >1. Still,

198 regarding pericarditis, the CX-024414 vaccine had greater SMRs than those of the
 199 TOZINAMERAN vaccine.

200 **Table 3.** Observed-to-expected analysis for myocarditis.

| Vaccine name | Person-time at risk (100,000 person-years) | Background incidence (lowest, highest) | Expected Myocarditis | Observed Myocarditis | SMR (95% CI) |
|-------------------------------|---|---|-----------------------------|-----------------------------|------------------------|
| Moderna (CX-024414) | 56.32 | 1 | 56.32 | 1,269 | 22.53 (21.31-23.81) |
| | | 10 | 563.2 | | 2.253 (2.13-2.38) |
| Pfizer-BioNTech (TOZINAMERAN) | 371.35 | 1 | 371.35 | 4,087 | 11.01 (10.67-11.35) |
| | | 10 | 3,713.5 | | 1.10 (1.07-1.14) |

Abbreviations: SMR, standardized morbidity ratio; CI, confidence interval.

201

202 **Table 4.** Observed-to-expected analysis for pericarditis.

| Vaccine name | Person-time at risk (100,000 person-years) | Background incidence (lowest, highest) | Expected Pericarditis | Observed Pericarditis | SMR (95% CI) |
|---------------------|---|---|------------------------------|------------------------------|---------------------|
| Moderna | 56.32 | 1 | 56.32 | 717 | 12.73 |

| | | | | | |
|-------------|--------|----|---------|-------|---------------|
| (CX-024414) | | | | | (11.82-13.70) |
| | | 10 | 563.2 | | 1.27 |
| | | | | | (1.18-1.37) |
| Pfizer- | 371.35 | 1 | 371.35 | 2,803 | 7.55 |
| BioNTech | | | | | (7.27-7.83) |
| (TOZINAME | | 10 | 3,713.5 | | 0.75 |
| RAN) | | | | | (0.73-0.78) |

Abbreviations: SMR, standardized morbidity ratio; CI, confidence interval.

203

204 DISCUSSION

205 In this study, we used data from EudraVigilance to evaluate the occurrence of
 206 myocarditis and pericarditis after mRNA COVID-19 vaccination. The majority of myocarditis
 207 and pericarditis' ADRs were reported among 18-64 years old people. Myocarditis occurred
 208 mostly among male cases, while for pericarditis, there were slightly more ADRs among males
 209 for CX-024414 and slightly more ADRs among females for the TONZINAMERAN vaccine.
 210 However, these results should be interpreted cautiously because data on the vaccination rate
 211 stratified by age and sex are absent in this study. The reporting rate of myocarditis and
 212 pericarditis per 1 million individual vaccinated-days in the study period was greater for CX-
 213 024414 compared to TOZINAMERAN. The SMR for myocarditis was greater than 1 for both
 214 vaccines (showing excess risk), with the CX-024414 vaccine having a greater SMR than
 215 TOZINAMERAN. For pericarditis, the results showed an SMR > 1 when considering the lowest
 216 background incidence; however, when the highest background incidence was considered, the
 217 TOZINAMERAN vaccine showed a smaller than 1 SMR. In either case, the pericarditis SMRs
 218 for CX-024414 were greater than that for TOZINAMERAN.

219 In Germany, surveillance data from the Paul Ehrlich Institute reported a rate for
220 myocarditis in men 18-29 years old of 11.71 cases per 100,000 COVID-19 Moderna vaccine
221 recipients in German data and 7.79 in the Moderna Global Safety Database.²² Furthermore, two
222 other large European studies reported the occurrence of myocarditis and pericarditis after
223 COVID-19 mRNA vaccination.²² The first one, the Nordic cohort study of 23 million residents
224 of Denmark, Finland, Norway, and Sweden, observed that during the 28-day risk periods
225 following vaccination, 1,092 incident myocarditis cases and 1,154 incident pericarditis cases
226 occurred. Among them, 106 and 123 myocarditis cases occurred following first- and second-dose
227 vaccinations with TOZINAMERAN, respectively, and 15 and 67 following CX-024414,
228 respectively. The second one, the population-based case-control study in France,²² showed a
229 large increase in the myocarditis odds within seven days after vaccination. In this study, the
230 association with the risk of myocarditis appeared particularly pronounced in young men under 30
231 years of age, particularly after the second dose of the CX-024414 vaccine (odds ratio (OR) 79.8;
232 95% CI [29.8-213.4]). A Danish population-based cohort study observed that vaccination with
233 the Moderna vaccine was significantly associated with an increased risk of myocarditis among
234 12-39 years old people, while vaccination with the Pfizer-BioNTech vaccine was significantly
235 associated with an increased risk among women.²³

236 Meanwhile, it is noteworthy to mention that the risk of myocarditis among adolescents
237 was found in one study to be lower after a booster compared to the second dose of the Pfizer-
238 BioNTech COVID-19 vaccine.²⁴

239 While an elevated risk of myocarditis following vaccination with mRNA COVID-19
240 vaccine was observed, the evidence regarding pericarditis remained equivocal. The population-
241 based case-control study in France observed an increased risk of pericarditis in people under 30

242 years of age, in particular after the second dose in men (OR 15.0, 95% CI [3.3-68.4]) and after
243 the first dose in women (OR 27.9, 95% CI [2.4-328.0]),²² while the Danish population-based
244 cohort study observed an increased risk of pericarditis among 12-39 years old people.²³ On the
245 other hand, Patone et al.²⁵ observed that there was no evidence of an increased risk of pericarditis
246 following vaccination, except in 1 to 28 days after the second dose of the Moderna vaccine.
247 Furthermore, Diaz et al.¹⁸ reported that pericarditis affected older patients later, after either the
248 first or second dose.

249 The elevated risk of myocarditis (and perhaps pericarditis) after receiving mRNA
250 COVID-19 vaccine should be evaluated in light of the greater risk of myocarditis or pericarditis
251 following SARS-CoV-2 infection.²⁵ Oberweis et al.²⁶ suggested that cardiac injury from SARS-
252 CoV-2 can be caused directly (e.g., through angiotensin-converting enzyme 2 binding in the
253 heart) and indirectly through a toxic inflammatory reaction with cytokine storm, with the indirect
254 mechanism being more frequent. Furthermore, the authors hypothesized that some children have
255 died from COVID-19 because they may have been more susceptible to heart damage from the
256 cytokine storm caused by COVID-19 than the standard respiratory distress syndrome seen in
257 adults.

258 Even though the rare occurrence of myocarditis and pericarditis can be deadly, the
259 majority of myocarditis cases linked to vaccines have been mild and self-limiting,¹⁷ whereas
260 SARS-CoV-2 infection may carry a serious risk of morbidity and mortality over time, especially
261 for the unvaccinated. Myocardial injury was highly common among hospitalized COVID-19
262 patients.²⁷ Patone et al.²⁵ emphasized that compared to the risk from COVID-19 vaccine, SARS-
263 CoV-2 infection was associated to a significant increase in the risk of myocarditis, pericarditis,
264 and cardiac arrhythmia-related hospitalization or death. Therefore, the benefits of SARS-CoV-2

265 mRNA vaccination that lowers both the risk of infection and the risk of hospitalization should be
266 considered when interpreting the results of our study.

267 Furthermore, our results should be interpreted in light of the fact that myocarditis and
268 pericarditis have also occurred following immunizations such as smallpox, influenza, hepatitis B,
269 or other vaccines.¹⁻³

270 Our study is subject to certain limitations. First, we cannot directly compare the reporting
271 rate of myocarditis or pericarditis to the incidence rate in the general EU/EEA population
272 because they represent different measures that use different definitions of the time at risk.
273 Consequently, whether the incidence of myocarditis or pericarditis is higher in vaccinated people
274 than in the general population is beyond the scope of this study. Since we do not know the exact
275 background incidence rate, which may vary substantially among different vaccine group
276 populations, as well as knowing that the data were based on different assumptions,²⁸ the findings
277 should be interpreted with caution. Second, we cannot exclude the possibility of ADRs'
278 registration underestimation. There is a possibility of underreporting myocarditis and
279 pericarditis, which can impose non-differential misclassification. Third, we were unable to
280 calculate myocarditis and pericarditis incidence for each vaccine that is adjusted for
281 demographics and other factors because the information on confounding is absent; except for sex
282 and age group, information on other variables was missing. Fourth, the reporting rates were not
283 standardized for age due to the unavailability of the data; therefore, we were unable to perform a
284 stratified OE analysis. A vaccine's safety profile may vary depending on the target population
285 (e.g., higher risks in the youngest age groups); therefore, comparing reporting rates for age
286 groups or countries should be avoided because it would introduce biases and inaccuracies.

287 **CONCLUSION**

288 To conclude, our study analysis supports an excess risk of myocarditis following the first
289 dose of the mRNA COVID-19 vaccine, but the direction of the relationship between pericarditis
290 and mRNA COVID-19 vaccine remains unclear. Future research is needed to calculate age and
291 sex standardized reporting rates, stratified OE analyses, as well as analyses following the second
292 or more doses of mRNA COVID-19 vaccine. The benefits of COVID19 vaccination exceed the
293 risks of adverse events; however, pharmacovigilance methods continue to play a pivotal role in
294 monitoring, identifying, and reducing ADR risk.

295 **ACKNOWLEDGEMENTS**

296 None.

297 **CONFLICT OF INTERESTS**

298 None declared.

299 **FUNDING**

300 This research did not receive any specific grant from funding agencies in the public, commercial,
301 or not-for-profit sectors.

302 **CONTRIBUTORSHIP**

303 Joana Tome – Research question generation, literature review, data analysis and interpretation,
304 manuscript preparation.

305 Logan T. Cowan - Manuscript preparation and review.

306 Isaac Chun-Hai Fung - Literature review, manuscript preparation, and review.

307 All authors attest they meet the ICMJE criteria for authorship.

308

309

310

311 REFERENCES

- 312 [1] Su JR, McNeil MM, Welsh KJ, et al. Myopericarditis after vaccination, Vaccine Adverse Event
313 Reporting System (VAERS), 1990–2018. *Vaccine*. 2021/01/29/ 2021;39(5):839-845.
- 314 [2] Bozkurt B, Kamat I, Hotez PJ. Myocarditis With COVID-19 mRNA Vaccines. *Circulation*.
315 2021;144(6):471-484.
- 316 [3] Mei R, Raschi E, Forcesi E, Diemberger I, De Ponti F, Poluzzi E. Myocarditis and pericarditis after
317 immunization: Gaining insights through the Vaccine Adverse Event Reporting System. *Int J Cardiol*. Dec
318 15 2018;273:183-186.
- 319 [4] EMA. COVID-19 vaccines: update on ongoing evaluation of myocarditis and pericarditis. . Available
320 at: [https://www.ema.europa.eu/en/news/covid-19-vaccines-update-ongoing-evaluation-myocarditis-](https://www.ema.europa.eu/en/news/covid-19-vaccines-update-ongoing-evaluation-myocarditis-pericarditis)
321 [pericarditis](https://www.ema.europa.eu/en/news/covid-19-vaccines-update-ongoing-evaluation-myocarditis-pericarditis). Accessed 4/27/2022.
- 322 [5] CDC. Advisory Committee on Immunization Practices (ACIP) June 2021 presentation slides.
323 Coronavirus disease 2019 (COVID-19) vaccines. . Available at:
324 <https://www.cdc.gov/vaccines/acip/meetings/slides-2021-06.html> Accessed 4/27/2022.
- 325 [6] PHAC. Statement from the Council of Chief Medical Officers of Health (CCMOH): update on COVID-19
326 vaccines and the risk of myocarditis and pericarditis. Ottawa, ON: Government of Canada. Available at:
327 [https://www.canada.ca/en/public-health/news/2021/10/statement-from-the-council-of-chief-medical-](https://www.canada.ca/en/public-health/news/2021/10/statement-from-the-council-of-chief-medical-officers-of-health-ccmoh-update-on-covid-19-vaccines-and-the-risk-of-myocarditis-and-pericarditis.html)
328 [officers-of-health-ccmoh-update-on-covid-19-vaccines-and-the-risk-of-myocarditis-and-](https://www.canada.ca/en/public-health/news/2021/10/statement-from-the-council-of-chief-medical-officers-of-health-ccmoh-update-on-covid-19-vaccines-and-the-risk-of-myocarditis-and-pericarditis.html)
329 [pericarditis.html](https://www.canada.ca/en/public-health/news/2021/10/statement-from-the-council-of-chief-medical-officers-of-health-ccmoh-update-on-covid-19-vaccines-and-the-risk-of-myocarditis-and-pericarditis.html). Accessed 4/27/2022.
- 330 [7] Grimaud M, Starck J, Levy M, et al. Acute myocarditis and multisystem inflammatory emerging
331 disease following SARS-CoV-2 infection in critically ill children. *Annals of intensive care*. 2020;10(1):69-
332 69.
- 333 [8] Das BB, Moskowitz WB, Taylor MB, Palmer A. Myocarditis and Pericarditis Following mRNA COVID-19
334 Vaccination: What Do We Know So Far? *Children (Basel)*. Jul 18 2021;8(7).
- 335 [9] Segal Y, Shoenfeld Y. Vaccine-induced autoimmunity: the role of molecular mimicry and immune
336 crossreaction. *Cell Mol Immunol*. Jun 2018;15(6):586-594.
- 337 [10] Root-Bernstein R, Fairweather D. Unresolved issues in theories of autoimmune disease using
338 myocarditis as a framework. *J Theor Biol*. Jun 21 2015;375:101-123.
- 339 [11] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in
340 Wuhan, China. *Lancet*. Feb 15 2020;395(10223):497-506.
- 341 [12] Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel
342 Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020;323(11):1061-1069.
- 343 [13] Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With
344 Coronavirus Disease 2019 (COVID-19). *JAMA Cardiology*. 2020;5(7):811-818.
- 345 [14] Klein NP, Lewis N, Goddard K, et al. Surveillance for Adverse Events After COVID-19 mRNA
346 Vaccination. *JAMA*. 2021;326(14):1390-1399.
- 347 [15] Shimabukuro T. Covid-19 vaccine safety updates - cdc.gov. *Centers for Disease Control and*
348 *Prevention*. June 23, 2021 2021:50.
- 349 [16] Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a
350 Nationwide Setting. *N Engl J Med*. Sep 16 2021;385(12):1078-1090.
- 351 [17] Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large Health Care
352 Organization. *New England Journal of Medicine*. 2021;385(23):2132-2139.
- 353 [18] Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and Pericarditis
354 After Vaccination for COVID-19. *JAMA*. 2021;326(12):1210-1212.
- 355 [dataset] [19] ECDC. Data on COVID-19 vaccination in the EU/EEA. 4/21/2022. Available at:
356 <https://www.ecdc.europa.eu/en/publications-data/data-covid-19-vaccination-eu-eea>. Accessed 2/16/2022.

- 357 [dataset] [20] EudraVigilance. European Database of suspected adverse drug reaction. *European*
358 *Medicines Agency*. Available at: <https://www.adrreports.eu/>. Accessed 2/16/2022.
- 359 [21] Abbattista M, Martinelli I, Peyvandi F. Comparison of adverse drug reactions among four COVID-19
360 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites. *Journal of*
361 *thrombosis and haemostasis : JTH*. 2021;19(10):2554-2558.
- 362 [22] EMA PRAC. Signal assessment report on myocarditis and pericarditis with Spikevax - COVID-19
363 mRNA vaccine (nucleosidemodified). *European Medicines Agency*. 2021:47.
- 364 [23] Husby A, Hansen JV, Fosbøl E, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis:
365 population based cohort study. *BMJ*. 2021;375:e068665.
- 366 [24] Kuehn BM. Myocarditis Adverse Event Less Common After COVID-19 Vaccine Booster. *JAMA*.
367 2022;327(14):1324-1324.
- 368 [25] Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias
369 associated with COVID-19 vaccination or SARS-CoV-2 infection. *Nature Medicine*. 2022/02/01
370 2022;28(2):410-422.
- 371 [26] Oberweis M-L, Codreanu A, Boehm W, et al. Pediatric Life-Threatening Coronavirus Disease 2019
372 With Myocarditis. *The Pediatric Infectious Disease Journal*. 2020;39(7).
- 373 [27] Sandoval Y, Januzzi JL, Jr., Jaffe AS. Cardiac Troponin for Assessment of Myocardial Injury in COVID-
374 19: JACC Review Topic of the Week. *J Am Coll Cardiol*. Sep 8 2020;76(10):1244-1258.
- 375 [28] Mahaux O, Bauchau V, Van Holle L. Pharmacoepidemiological considerations in observed-to-
376 expected analyses for vaccines. *Pharmacoepidemiology and drug safety*. 2016;25(2):215-222.
377